Overview of Cogstate's FY24 financial results and future outlook

Cogstate Ltd (ASX: $CGS) has published its FY24 Investor Briefing, presenting a summary of the financial results for the year ended 30 June 2024. The briefing also includes commentary on the business and financial outlook. Investors are invited to join Cogstate CEO, Brad O'Connor, for a live webcast of the presentation on Thursday 22 August 2024 at 8:30am Australian Eastern Standard Time. The presentation material is available on the Cogstate Investor Centre homepage.

Executive commentary on FY24 performance and future prospects

Cogstate's FY24 Investor Briefing highlights the company's focus on optimizing brain health assessments to advance the development of new medicines and enable earlier clinical insights in healthcare. The briefing emphasizes Cogstate's support for leading-edge research needs of biopharmaceutical companies and academic institutions, as well as its commitment to providing primary care physicians and consumers with scientifically validated digital measures of cognition. The company's partnership with pharmaceutical company Eisai to distribute Cogstate assessments in the USA & Asia is also underscored.

Summary of FY24 results and future outlook

Cogstate's FY24 Investor Briefing showcases the company's impressive revenue growth in the context of Clinical Trials sales and its strategic focus on CNS diseases, particularly Alzheimer's R&D. The renegotiation with Eisai is highlighted as a commercially sound move that provides important options for growth. The briefing also outlines Cogstate's technology investment, margin improvement, and strong start to FY25. Looking ahead, Cogstate aims to capitalize on the significant market opportunity in CNS diseases, grow revenue and profit in FY25, and explore exciting pilot programs outside of clinical trials with re-secured IP. The company's commitment to scientific consulting, scale management, remote assessment, and digital cognitive assessments positions it for continued success in the healthcare and pharmaceutical sectors.